Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus ddMVAC before radical cystectomy for muscle-invasive bladder cancer
NL-OMON61138Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in bladder cancer, muscle-invasive bladder cancer (MIBC), sponsored by AstraZeneca. Started Aug 2026; status: recruiting.
02
Drugs
durvalumab
03
Conditions
bladder cancermuscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NL-OMON61138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61138.